Related Experiment Video

Updated: Jun 28, 2026

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Antiangiogenic drugs in ovarian cancer

G C Kumaran1, G C Jayson, A R Clamp

  • 1Department of Medical Oncology, Cancer Research UK, Manchester, UK. gkumaran@picr.man.ac.uk

British Journal of Cancer
|November 13, 2008
PubMed

Insights

Antiangiogenic treatments show promise for treating ovarian cancer, a leading cause of death in women. This review covers the scientific basis, clinical progress, and side effects of these novel therapies.

Area of Science:

  • Oncology
  • Gynecologic Oncology
  • Translational Medicine

Background:

  • Ovarian cancer remains a significant global health challenge, contributing substantially to female morbidity and mortality.
  • The tumor microenvironment, particularly angiogenesis, plays a critical role in ovarian cancer progression and metastasis.
  • Conventional therapies often face limitations, necessitating the exploration of novel treatment strategies.

Purpose of the Study:

  • To review the scientific rationale for employing antiangiogenic therapies in ovarian cancer.
  • To summarize the clinical development and current status of antiangiogenic drugs in ovarian cancer treatment.
  • To delineate the specific toxicities associated with antiangiogenic treatment modalities.

Main Methods:

  • Literature review of preclinical studies and clinical trials.
  • Analysis of data on antiangiogenic drug efficacy and safety.
  • Synthesis of information regarding the mechanism of action and clinical application.

Main Results:

  • Antiangiogenic treatments target key pathways involved in tumor vascularization and growth.
  • Several antiangiogenic agents have demonstrated efficacy in clinical trials, leading to regulatory approvals.
  • Common toxicities include hypertension, proteinuria, and bleeding, requiring careful patient monitoring.

Conclusions:

  • Antiangiogenic therapy represents a valuable addition to the ovarian cancer treatment armamentarium.
  • Further research is ongoing to optimize the use of these agents and mitigate side effects.
  • Personalized approaches may enhance the effectiveness of antiangiogenic strategies in ovarian cancer management.

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...